end stage of liver diseases
Conditions
Interventions
stem cells therapy:PBSC therapy
Control:Routine medicine therapy
Sponsors
Fourth Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: Aged 18 to 69 years, CHB,CHC,NAFLD,AFLD, DILI,and idiopathic cirrhosis; ultrasonographic or CT evidences of cirrhosis and portal hypertension, mild ascitis,abnormal serum albumin20s, hematoglobin>=7.0 g/L, platelet >=300 000/mL, a Child-Turcotte-Pugh (CTP) score or prior CTP score >=7 at screen.
Exclusion criteria
Exclusion criteria: severe ascites, history of moderate to severe hepatic encephalopathy or variceal bleeding during the last one month before enrolment; serum creatinine >=2 mg/dL, serum sodium<125 mEq/L; serum total bilirubin more than 3 mg/dL; presence of active untreated infectious disease; presence of hepatic, portal, or splenic vein thromboses on Doppler ultrasonography; presence of severe comorbid diseases (e.g., severe renal, respiratory, or cardiac disease), or presence of any type of malignancy; history of alcohol abuse, or use of hepatotoxic drugs within the last six months before enrolment; active substance abuse; pregnancy or lactation; can not sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Death;liver transplantation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Child pugh score, MELD;ALT, AST, TBIL;ALB, CHO, CHE, AT; | — |
Countries
China
Contacts
Public ContactHan Ying
Outcome results
None listed